Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer.
A L NashY RenJ K PlichtaL H RosenbergerA M B van den BrueleM L DiNomeK WestbrookE Shelley HwangPublished in: Annals of surgical oncology (2023)
RS retains its prognostic value in younger patients with early stage HR-positive, HER2-negative breast cancer. Chemotherapy survival benefit was limited to patients aged 40-50 with pN1 disease and RS of 31-50. Therefore, chemotherapy decision-making should be especially preference-sensitive in women aged 40-50 with intermediate RS, where it may not provide a survival benefit for many women.
Keyphrases
- early stage
- free survival
- locally advanced
- polycystic ovary syndrome
- decision making
- ejection fraction
- newly diagnosed
- pregnancy outcomes
- squamous cell carcinoma
- gene expression
- radiation therapy
- copy number
- dna methylation
- genome wide
- patient reported outcomes
- chemotherapy induced
- lymph node
- young adults
- adipose tissue
- metabolic syndrome
- middle aged
- patient reported